grazoprevir + uprifosbuvir + elbasvir

This combination drug is an investigational, oral, direct-acting antiviral regimen for hepatitis C virus (HCV) infection, consisting of grazoprevir (an HCV NS3/4A protease inhibitor), uprifosbuvir (an HCV NS5B RNA polymerase inhibitor, also known as MK-3682), and elbasvir (an HCV NS5A inhibitor). It was tested for pan-genotypic activity against HCV, particularly genotypes 1, 2, and 3, and evaluated for shortened treatment duration. The drugs work by blocking three different steps in the HCV replication cycle: protease function, RNA polymerase activity, and NS5A-mediated viral assembly. In phase 2 trials (C-CREST 1 & 2), this combination demonstrated antiviral efficacy in patients without cirrhosis, though slightly lower SVR12 (sustained virologic response at 12 weeks post-treatment) rates were noted in genotype 2 compared to other experimental regimens. Safety profile included headache, fatigue, and nausea as the most common adverse events; serious adverse events were rare and not considered drug-related.

Other names

grazoprevir + uprifosbuvir + elbasvir